Headquartered in New York (USA), Pfizer Inc.
a global giant in Pharmaceutical industry holds one of the most experienced portfolio (founded in 1849) in therapeutic drugs and services across the world. With an aim to address the diverse healthcare medical needs of the patients around the world, Pfizer has kept expanding it's R&D base and hence the product lines round the clock. From Lipitor, Idamycin, Cardura to Viagra etc almost every product of Pfizer has dominated the market post-launch.
Here is a brief overview of the recent developments at Pfizer Inc, with the information on latest job opportunities in this esteemed pharmaceutical firm.
- Results of Zoetis Inc. Exchange Offer Declared
Pfizer Inc., the owner of common stocks of Zoetis Inc. had offered a share exchange offer, wherein the Zoetis common stock shares could be exchanged with Pfizer common stock shares. The exchange offer had expired at 00:00 hrs, NY City time, June 21, 2013. And, the results of the exchange offer were declared on Thursday, June 27, 2013. As per the declaration 0.9898 shares of Zoetis common stock were exchanged for every 1 share of Pfizer common stock.
For Details on the declaration Click here
- TEVA and Sun Pharmaceuticals Settle for $2.15 billion penalty for Infringement of Pfizer's Protonix Patent
After a long legal battle of nearly 10 years, Pfizer (and Pfizer’s subsidiary Wyeth and Takeda) have successfully obtained the settlement of $2.15 billion from TEVA Pharmaceuticals and Sun Pharmaceutical Industries, Limited for the infringement of the patent for their blockbuster medicine Protonix, by launching the generics before the expiry of the patent in January 2011. As a part of the settlement, Teva will pay $1.6 billion and Sun will pay $550 million to Pfizer and Takeda.
For Details on the story, Click here
- FDA Accepts Pfizer's Application for Reviewing and Expanding the XELJANZ Labeling
Pfizer announced on June 21, 2013 that FDA has accepted to review it's application for expanding the labeling of XELJANZ
(tofacitinib citrate), used for severely active Rheumatoid Arthritis to include it's efficacy in inhibition of Progression of Structural Damage too. XELJANZ is the first FDA approved medicine in the class of Janus kinase (JAK) inhibitors, and is effective in treating the patients unresponsive or intolerant to Methotrexate (MTX).
For Details, Click here
Following are the recent job openings at Pfizer in United States:
Note down the JOB ID and Apply here
A. Quality Assurance:
B. Research & Development
Keep an eye on this thread for further updates.
Thanks for Reading!